Breast Cancer News
The Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp; Pfizer), a biosimilar to Herceptin (trastuzumab; Genentech).
The Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab; Genentech) in combination with Abraxane.
A study of patients with HER2-positive early-stage breast cancer receiving fixed doses of trastuzumab found that 67% and 38% of patients were underdosed in the loading and maintenance settings, respectively.
The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer.
Testing should be made available to all patients with a family or personal history of breast cancer, according to the American Society of Breast Surgeons.
This study provides evidence that birinapant could enhance sensitivity to TNF, effectively boosting the activity of CAR-T therapy in solid tumors.
Prior to treatment, HER2 testing using FDA-approved tests should be performed.
Breast cancer models showed certain neoadjuvant chemotherapy promoted prometastatic behavior.
Celltrion and Teva announced that the FDA has approved Herzuma (trastuzumab-pkrb) injection, a new biosimilar to Herceptin (trastuzumab; Genentech) for certain HER2-overexpressing breast cancer indications.
Researchers reported that 3 years after whole-breast irradiation and a tumor bed boost, outcomes with hypofractionation and conventional fractionation are similar.
Investigators found that incident osteopenia and osteoporosis are significantly higher in young survivors of breast cancer.
CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.
Researchers find that surgical decision making is often driven by factors beyond extent of disease.
Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.
The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.
The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.
Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.
Partial-breast irradiation failed to meet protocol-defined measures for equivalence.
Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.
CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.